Drug Profile
C 21
Alternative Names: C-21; Compound 21 - Vicore Pharma; PROJECT 1; VP 01Latest Information Update: 13 Feb 2024
Price :
$50
*
At a glance
- Originator Vicore Pharma
- Class Antifibrotics; Antihyperglycaemics; Carbamates; Imidazoles; Small molecules; Sulfones; Thiophenes; Vascular disorder therapies
- Mechanism of Action Angiotensin type 2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III COVID 2019 infections
- Phase II Idiopathic pulmonary fibrosis; Raynaud's disease
- Phase I Diabetes mellitus; Pulmonary arterial hypertension
- No development reported Dupuytren's contracture; Fibrosis
Most Recent Events
- 09 Feb 2024 C 21 licensed to Nippon Shinyaku in Japan
- 06 Sep 2023 Vicore Pharma intends to initiate a phase IIb ASPIRE trial for Idiopathic pulmonary fibrosis in the first half of 2024
- 20 Jun 2023 Vicore Pharma completes a phase I trial in Diabetes mellitus in Sweden (unspecified route) (NCT05831644)